Mitoxantrone hydrochloride liposome is a unique active ingredient for preparing drugs for treating breast cancer. The breast cancer is preferably advanced breast cancer. A method for treating the breast cancer includes to administer mitoxantrone hydrochloride liposome in a therapeutic effective amount to breast cancer patients, and the therapeutic effective amount means 8-30 mg/m.sup.2, according to mitoxantrone. Clinical trial results show that the mitoxantrone hydrochloride liposome has better efficacy and fewer adverse reactions, and especially significantly reduced cardiotoxicity, compared with a common mitoxantrone hydrochloride injection.

Mitoxantrone hydrochloride liposome is a unique active ingredient for preparing drugs for treating breast cancer. The breast cancer is preferably advanced breast cancer. A method for treating the breast cancer includes to administer mitoxantrone hydrochloride liposome in a therapeutic effective amount to breast cancer patients, and the therapeutic effective amount means 8-30 mg/m.sup.2, according to mitoxantrone. Clinical trial results show that the mitoxantrone hydrochloride liposome has better efficacy and fewer adverse reactions, and especially significantly reduced cardiotoxicity, compared with a common mitoxantrone hydrochloride injection.

This document relates to methods and materials involved in assessing and/or treating mammals (e g , humans) having cancer. For example, methods and materials that can be used to determine whether or not the cancer is likely to be responsive to a particular cancer treatment (e.g., a cancer immunotherapy or a cancer chemotherapy) are provided. For example, methods and materials that can be used to treat a mammal by administering one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to a particular cancer treatment also are provided.

This document relates to methods and materials involved in assessing and/or treating mammals (e g , humans) having cancer. For example, methods and materials that can be used to determine whether or not the cancer is likely to be responsive to a particular cancer treatment (e.g., a cancer immunotherapy or a cancer chemotherapy) are provided. For example, methods and materials that can be used to treat a mammal by administering one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to a particular cancer treatment also are provided.

The present invention provides compositions comprising one or more active pharmaceutical ingredients, wherein the compositions are in the form of high solids concentration pastes capable of being injected in relatively low volumes into an animal using standard commercially available syringes. The invention also provides methods of making such compositions, particularly those compositions comprising high molecular weight active ingredients (e.g., antibodies, enzymes and other proteins and peptides) at relatively high therapeutic concentrations in the high solids concentration pastes. The invention further provides methods of using such formulations in treating, preventing and/or ameliorating certain diseases and physical disorders in animals, including humans, in need thereof. The invention also provides kits comprising the formulations of the invention and a suitable syringe, which in some aspects may be pre-loaded or pre-filled with a composition of the invention.

The present invention provides compositions comprising one or more active pharmaceutical ingredients, wherein the compositions are in the form of high solids concentration pastes capable of being injected in relatively low volumes into an animal using standard commercially available syringes. The invention also provides methods of making such compositions, particularly those compositions comprising high molecular weight active ingredients (e.g., antibodies, enzymes and other proteins and peptides) at relatively high therapeutic concentrations in the high solids concentration pastes. The invention further provides methods of using such formulations in treating, preventing and/or ameliorating certain diseases and physical disorders in animals, including humans, in need thereof. The invention also provides kits comprising the formulations of the invention and a suitable syringe, which in some aspects may be pre-loaded or pre-filled with a composition of the invention.

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

The present invention provides compositions and methods for treating and preventing cancer. The invention comprises an inhibitor of epigenetic regulators, including MLL1, MLL2, MOZ, menin, WDR5, or a combination thereof. In one embodiment, the invention provides a personalized method of treating a cancer as dependent upon its epigenetic signature.